it is an object of the present invention to disclose a pharmaceutical dosage form containing pparα agent , especially fenofibrate , and at least a hmg - coa reductase inhibitor of the statin family . it is another object of the present invention to disclose a pharmaceutical dosage form containing pparα agent , especially fenofibrate , and at least a hmg - coa reductase inhibitor contained in a capsule or a tablet . another object of the present invention is to disclose a pharmaceutical dosage form containing pparα agent , especially fenofibrate , and at least a hmg - coa reductase inhibitor with increased bioavailability for both the pparα agent , especially fenofibrate , and all the hmg - coa reductase inhibitor . also an object of the present invention is to disclose a pharmaceutical dosage form containing pparα agent , especially fenofibrate , and at least a hmg - coa reductase inhibitor from which at least the pparα agent , especially fenofibrate , has an increased bioavailability . also an object of the present invention is to disclose a pharmaceutical dosage form containing pparα agent , especially fenofibrate , and at least a hmg - coa reductase inhibitor from which at least one of the hmg - coa reductase inhibitors have an increased bioavailability . the formulation contains advantageously at least one hydrophilic agent ( hlb & gt ; 10 ) and / or one or more stabilizing agent ( s ) e . g . one or more antioxidant or preservative agent or a combination of both preservative and antioxidant agents . according to the invention , a pharmaceutical composition useful for administration to a mammal comprises in a same dosage form an effective amount of at least one peroxisome proliferator activated agent ( pparα ), an effective amount of at least one hmg - coa reductase inhibitor derivative of the statin family , and at least one polyglycolized glyceride or another derivative of glyceride . preferably , the composition comprises at least one peroxisome proliferator activated agent ( pparα ) under the form of semi - solid composition ( containing at least one polyglycolized glyceride or another derivative of glyceride ) and at least one hmg - coa reductase inhibitor derivative of the statin family under the form of a coated tablet , both the semi - solid form and the tablet being filled in one single pharmaceutically acceptable capsule preferably , the composition further comprises at least one hydrophilic disintegrating agent . examples of disintegrating agents are sodium starch glycolate , sodium croscarmellose , crospovidone , starch , colloidal silicone dioxide or another pharmaceutically accepted disintegrating agent and combinations thereof , sodium starch glycolate being preferred . in the composition of the invention , the pparα agent is advantageously a compound of the fibrate family , preferably a compound selected from the group consisting of fenofibrate , ciprofibrate , clofibrate , gemfibrozil , bezafibrate and combinations thereof . especially , the pparα agent is fenofibrate . the pharmaceutical composition of the invention is preferably in a form suitable for the oral administration of the active agents . the polyglycolised glyceride has advantageously an hlb balance above 10 , preferably above 11 , most preferably above 12 . according to an embodiment , the melting point of the said composition is below 90 ° c ., preferably below 80 ° c ., most preferably below 70 ° c . the pharmaceutical composition of the invention contains advantageously one or more antioxidant and / or preservative agent ( s ), such as a vitamin e derivative and / or a methoxyphenol derivative and / or a combination thereof . the pharmaceutical composition of invention contains advantageously a wetting agent . the composition of the invention further contains advantageously a polyethylene glycol or a mix of polyethylene glycol with different molecular mass ; and / or a suspension stabilizer , such as a cellulose derivative , hydropropylcellulose . the composition of the invention is adapted for the administration of specific amount of active agent per dose . advantageously , the amount of pparα , preferably fenofibrate , per dose is between 30 and 400 mg , while the amount of statin per dose is between 5 and 100 mg , the amount of statin per dose being preferably lower than the amount of pparα per dose , most preferably comprised between 0 . 01 and 0 . 5 times the amount of pparα per dose . the composition of the invention is for example filled in hard gelatine capsules , hypromellose capsules or in other pharmaceutically acceptable capsules . according to a preferred detail of the composition , the composition is with the proviso that the pparα , preferably fenofibrate , is not co - micronized , and / or , preferably and , with the proviso that the statin is not co - micronized . according to preferred embodiments , the weight ratio ppar agent + statin / hydrophilic disintegrating agent is comprised between 100 and 0 . 1 , advantageously between 50 and 2 , preferably between 40 and 4 , more preferably between 6 and 25 , such as 8 , 10 , 12 , 14 , etc . according to a further detail of a preferred embodiment , the weight ratio ppar + statin agent / polyglycolized glyceride ( s ) is comprised between 10 and 0 . 1 , advantageously between 5 and 0 . 2 , preferably lower than 1 , more preferably between 0 . 8 and 0 . 3 , such as about 0 . 8 , 0 . 7 , 0 . 6 , 0 . 5 , 0 . 4 . for example , at least one hmg - coa reductase inhibitor derivative of the statin family is advantageously selected from the group consisting of pravastatin , simvastatin , lovastatin , fluvastatin , atorvastatin and cerivastatin . simvastatin , lovastatin , pravastatin and mixtures thereof . the pharmaceutical composition of the invention advantageously further contains a polyethyleneglycol derivative ( peg ). the amount of peg is advantageously comprised between 0 . 2 and 5 times the amount of stain present in the composition , preferably between 0 . 5 and 2 times the amount of statin present in the composition . according to a specific embodiment , the composition contains one or more antioxidant and / or preservative agent ( s ), one polyethylene derivative , and one hydrophilic wetting agent . the semi - solid composition may be a suspension , an emulsion or a micro - emulsion . the hmg - coa reductase inhibitor agent and the fibric acid derivative may be partially or totally dissolved in the semi - solid matrix formed by the excipients . the advantages of the semi - solid formulations are multiple for hmg - coa reductase inhibitors : protection of the active ingredient from air and humidity , possibility of increasing the dissolution rate of the molecule and hence of bioavailability , diminution of the risk of contamination of the operator , diminution of the risk of cross contamination , no possibility of demixing under the effect of vibrational mixing during manufacturing process , facility of the production process . the choice of the nature of the formulation of course influenced the stability of the pharmaceutical form and the bioavailability of the drug contained in it . generally , a maximum bioavailability is achieved by preparing and keeping the drug in the amorphous / solubilized state in a solid dispersion or in a lipid - based formulation . for these systems , the barrier we are avoiding is the compound & lt ;& lt ; washing - out & gt ;& gt ; of solution to a large extent into a insoluble crystalline form during the dissolution / release step in vivo . these systems may consist of suspension , emulsion , microemulsion , self - emulsifying drug delivery systems ( sedds ) or self - emulsifying microemulsion drug delivery system ( smedds ). microemulsions have the added advantage over suspensions such as emulsions and dispersions since thermodynamically they are more stable , that they can be manufactured with little energy input and have generally a longer shelf - life . the formation of oil - in - water ( o / w ) and water - in - oil ( w / o ) microemulsions usually involves a combination of 3 - 5 basic compounds i . e . oil , surfactant , cosurfactant , water and electrolytes . the challenge is to select for a particular application oil ( s ) and surfactant ( s ) that are acceptable from a toxicological perspective and that allow to obtain a high bioavailability of the drug . the assessment of the quality of semi - solid lipid based formulations is quite difficult since the in vitro dissolution test is of little help . indeed , the in vitro / in vivo correlation between dissolution and bioavailability is very poor for this kind of formulation . other analytical tools are available to the formulator to try to predict the in vivo bioavailability of isotretinoin from various formulations like the caco - 2 cells model , the assessment of the percentage of drug dissolved in the formulation , differential scanning calorimetry , microscopy , . . . nevertheless , none of them present a guarantee of in vitro / in vivo correlation and ultimately only pharmacokinetic studies on human subjects are reliable to assess the bioavailabiltiy of the drug . advantageously , the melting point of the final composition will be below 80 ° c ., preferably below 60 ° c . advantageously , an emulsifier may be added ( e . g distilled monoglycerides , myverol ®, gillco , us ) to the formulation in order to increase the solubilization of the hmg - coa reductase inhibitor . advantageously , the oral pharmaceutical composition may contain a solubilizing agent . this solubilizing agent is advantageously water and hcl soluble . an example of this kind of solubilizing is diethylene glycol monoethyl ether ( transcutol ®), gattefosse ). also advantageous for the stability and the bioavailability of the composition is the addition of an antioxidant agent such as either a tocopherol derivative like tocopherol ( vitamine e ), tocopherol acetate , vitamine e tpgs or a methylphenol derivative like butylhydroxyanisol ( bha ) or butylhydroxytoluene ( bht ). the addition of a polymer able to control the recristallisation of the active ingredient may also be useful when the active ingredient is not completely dissolved in the semi - solid matrix . the role of the polymer is ( i ) to stabilize the semi - solid formulation by increasing the viscosity of the composition and ( ii ) to avoid the growth of particles of active ingredient that are not solubilized ( or formed during the cooling of the composition ) by forming a matrix in the semi - solid composition . examples of such agents are cellulose derivatives such as hydroxypropylcellulose , hypromellose and methylcellulose . a wetting agent may also be added advantageously to the said composition when a very fast release in needed . example of such agents are na croscarmellose , na carboxymethylcellulose or reticulated póvidone . the effect of the wetting agent is strongly dependent on the nature of the active ingredient and on the nature of the semi - solid matrix . one of the advantages of the invention relates to the easiness of the manufacturing process of the medication and the rapidity and easiness of the pharmaceutical composition . briefly , the inactive ingredients are used as molten together . in an adequate tank the active ingredient is added to the molten mass and once the solution mass is homogenous , the molten is filled into pharmaceutically acceptable capsules e . g . hard gelatin capsules or hypromellose capsules . the capsules are then cooled and thereafter adequately packaged . the example 3 hereinabove describes a composition corresponding to the present invention wherein the fenofibrate is formulated as a semi - solid formulation and the pravastatin as a coated tablet formulation , the fenofibrate and pravastatin formulations being filled as a single composition in one single hard gelatin capsule . in the present specification , the term “ improved bioavailability ” relates to the human bioavailability of the drug ( s ) in humans . the bioavailability of a drug is defined as the rate and extent to which the active substance or active moiety is absorbed from a pharmaceutical form and becomes active at the site of action . the bioavailability is essentially quantified by the area under the plasma concentration curve ( auc ) and the maximal plasma concentration ( c max ). consequently , an improved form of the invention presents a higher bioavailability ( auc and / or c max ), preferably a significantly higher bioavailability than the reference , namely the actually commercialized fenofibrate form or / and the actually commercialized hmg - coa reductase form , the drug being taken via the oral route at the same dose . the preferred form of the invention presents a higher bioavailability ( auc and / or c max ), preferably a significantly higher bioavailability than the references which are respectively the actually commercialized form of fenofibrate and the actually commercialized form of hmg - coa reductase inhibitor , when the products are taken via the oral route at the same dose . the improved bioavailability is for example improved of at least 10 %, advantageously of at least 15 %, preferably of at least 20 % with respect to the bioavailability of the reference . the compositions of the various formulations f1 to f9 of examples 1 to 3 have been repeated , except that the fenofibrate has been replaced by ciprofibrate , clofibrate , gemfibrozil , bezafibrate , a combination of bezafibrate ( 50 %) and fenofibrate ( 50 %).
oral pharmaceutical composition containing , in the same pharmaceutical form , effective amounts of a hmg - coa reductase inhibitor derivative and of a ppara , especially fenofibrate . also described is the use of some inactive ingredients which allow to improve the dissolution and / or bioavailability of the drugs from the said composition .